Seach Medical Group Ltd.

Investor Presentation • Apr 8, 2021

WE ARE SEACH

Pioneers of the Israeli Medical Cannabis Industry

Investors Deck – Financial Statements of 2020

A p r i l 2021

Legal Disclaimer

Clarification: This Company's Investors Deck (the "Presentation") includes general and partial information only, and should be read in conjunction with the Company's immediate and periodic reports published from time to time (the "Company's Reports "), including its financial statements attached to the Company's Periodic Report for the year 2020, dated March 21, 2021, and its Periodic Report for the year 2019, dated March 15, 2020 (Reference No.: 2021-01-039375 and 2020-01-024609 respectively) (the "Periodic Reports"). In any event of discrepancy or inconsistency between the information specified in this Presentation and the information appearing in the Company's Reports or the Periodic Report, the latter shall prevail, as the case may be.

This Presentation does not constitute an offer to purchase or sell securities or an invitation to receive such offers and is intended to provide information only. The information does not constitute a recommendation or opinion nor does it constitute a substitute for the discretion or collection and analysis of independent and additional information of any potential investor. The images shown in this presentation are for illustration purposes only.

The information in the presentation does not relate to the specific considerations or requirements of any potential investor or to legal, accounting, tax, regulatory and other aspects related to the investment by such investor. In any event this Presentation does not constitute any advice or guidance. It does not constitute a substitute for the receipt of professional advice and guidance by a person authorized to give it. Every potential investor should seek such advice and guidance in connection with his potential investment, including tax consultation that takes into consideration his data and tax status.

The Presentation includes plans for operations and/or moves and/or evaluations of the Company based on the Company's operations as of today, that constitutes forward-looking information, as the term is defined in the Securities Law, 5728-1968, including forecasts, business goals, evaluations and standards, and any other information, in any manner provided, relating to the future events or matters, the realization of which is uncertain and not under the Company's control. The realization and/or non-realization of the forward-looking information as stated can be affected by risk factors that characterize the Company's operations, as well as developments in the economic environment and external factors that affect its operations, all as specified in the Company's Reports and Periodic Report. It is also clarified that the Company's plans and strategy included in this Presentation are correct as of the date of its publication and may change in accordance with the decisions of the Company's board of directors. For the removal of any doubt, it is clarified that the company does not undertake to update and/or change the information contained in the Presentation in order to reflect events and/or circumstancesthat will apply after the preparation of this Presentation.

2020 financial overview

• 2020 Revenues reached NIS 37 Million
• 2020 Profit and Adjusted Profit* amounted to NIS 12 Million and 18 Million, Respectively

Technological and R&D leader

• Execution of clinical trials to develop the next generation of medical Cannabis products
• Investments in various technological oriented companies within the Cannabis sector

Focused on brands & several markets

• Leading the Israeli market with top brands: Nitzan, Axiban
• Executed first commercial export during November 2020, additional shipments to different countries
• Worldwide collaborations for supply of top-quality medical Cannabis products

Experience & production capacity

• Has been cultivating and supplying medical Cannabis to thousands of patients in the last 14 years
• Increasing production capacity in company's facility & through domestic and international joint ventures
• Genetic bank with more than 500 genetic lines

Pioneering the medical Cannabis field since 2002

Nir Zichlinskey

Chairman

Owner and CEO of SRI GLOBAL GROUP, served as second to the CEO of Arison investment, CPA – previously served as a senior partner at BDO Ziv Haft.

Yaakov Amidror

Director

General in reserves, previously head of the national security headquarters, researcher of strategy & security worldwide, a member of the board of the Company of Israel, and adviser to several startups.

Hezi Cohen

External Director

CPA and financial consultant to real-estate project companies and to private companies. In addition, serves as an external director to several companies in the private sector.

Board of Directors

Itamar Elitzur

Independent Director

Has vast experience in strategic and economic consulting to high-profile organizations in the public and private sector.

Serves as head of corporate communication and IR at Migdal Group and as an external director in several companies.

The Israeli Cannabis market

• Number of patients as of February 2021: 85,074
• Estimations for 70% growth rate to 140,000 patients in 2022

Increasing production capacity

Increasing production capacity by upgrading the greenhouses with modular cultivation systems

Strategic agreements with sub-farms to increase production capabilities while receiving royalties from sub-farms

Import of top-quality Cannabis inflorescences from leading companies worldwide

Seach's Brands

• Over the course of a decade unique strains have been developed in accordance with medical standards and patients needs
• Products and brands are widely sold to licensed pharmacies in Israel
• New products are under development and will enter the market in accordance with regulation developments
• Seach is focusing on building products and brands with an emphasis on patient user experience

Co-brand collaboration with Rafa & Panaxia

• Collaboration for production and sale of Axiban Cannabis oils between Seach, Panaxia and Rafa which integrates several parts of value chain

Co-brand collaboration with Hadassah

• Collaboration for production and sale of mutual Cannabis oils brand between Seach and Hadassah hospital

• Execution of clinical trials for development of innovative products based on Seach's formulations
• Potential clinical trials include diabetic neuropathy, autism in young people, pain, Alzheimer's and more
• Nitzan Spectrum Cannabis oil is based on a designated formulation which was developed by Seach in the past years

December 2019

Beginning of Nitzan Spectrum clinical trial to examine its therapeutic effect on young people with ASD disorder

The Israeli medical Cannabis market is expected to reach 140,000 patients in 2022

Novembe r 2020

For the f ir s t tim e i n the hi s tor y o f Isr ae l, S eac h e xec uted commerci al expor t o f medic al C a nna bi s fro m Is r a e l

Ma rch 2021 E xec utio n o f the la rg es t-sca le comme rci al expor t by an Is r a e l i c o m pa ny - 120 k g o f i nf l o r e sce nce s to A us tr a l i a

Seach International

18

Sarrio Hellas S.A Greece

• Seach holds 52.5% of Sarrio Hellas S.A shares, together with Israeli and Greek partners
• •In January 2020 Sarrio received an initial license for cultivation, manufacturing, marketing and selling of medical Cannabis in Greece and export to European countries
• Sarrio owns 60,000 sq. meters land located 80 kilometers north of Athens by the city of Thiva
• The facilities are in planning and construction licensing processes and are expected to include hybrid greenhouses and a manufacturing plant
• Cultivation and manufacturing shall be done in compliance with GACP and EU-GMP standards
• Potential production capacity of tens of tons of Cannabis inflorescence per year

Strategic activities in designated countries

Seach

Sarrio Hellas S.A Greece

Why Greece?

• Relatively developed Cannabis regulationsin comparison to other European countries
• The Greece government has declared the Cannabis industry as a strategic growth engine
• Greece is a gate to the EU
• Relatively low operational costs (labor and resources)
• •Ideal weather and climatic conditions(similar to Israel)
• Supporting business environment

Strategic activities in designated countries

Initial license January 2020

Green Element BV

Netherlands

• The company engages in manufacturing, marketing and selling of CBD-productsin Europe
• The company operates, inter-alia, in the field home-pets' products, based on a network of local veterinary clinics
• The company has signed several commercial agreements for the production of CBD inhalers, CBD toothpicks, and CBD powder - for mixing in drinks
• This collaboration will enable Seach to develop a CBD-enriched line of productsin Europe
• In accordance with expected regulatory developments in Israel in the field of CBD, Seach will be able to import existing product lines from the Netherlands

Seach International

Strategic activities in designated countries

Seach has entered into a long-term agreement with GMPC (Global Medical Cannabis Producers Corporation) to grant exclusive right of use in Canada to GMPC for the cultivation, marketing and sales of products based on Seach's specific formulations and strains in Canada in exchange for royalties from their sales

Harmony Foundation

USA

Seach International

Strategic activities in designated countries

Seach has entered into a long-term agreement with Harmony Foundation, which is incorporated in the US and holds licenses to cultivate, manufacture and distribute medical Cannabis products in New Jersey. Under the agreement Seach grants Harmony a non-exclusive right to manufacture, market and sell Seach's products in New Jersey in exchange for royalties from their sales

Holdings in innovative technology companies

Medical Group

Eybna Technologies Activity - 39.5%

• An R&D company which conducts research on the medical activity of phytochemicals found in Cannabis with a strong emphasis on a group of substances called Terpenes
• Eybna develops and manufactures natural terpenes formulations with various medical effects for use in the Cannabis, food, cosmetics and pharma industries
• Eybna's R&D center and factory are in Israel, the marketing and sales offices are in California, USA
• Eybna's formulations are used as essential component in leading products of several of the world's best-known Cannabis brands
• Analysis of terpene profiles of Seach's varieties and development of terpene formulations to enrich Cannabis oil products
• A platform for the development and production of a new generation of medical Cannabis products with increased efficiency and consistency
• Eybna funds and conducts groundbreaking academic research at the Hebrew University and Bar Ilan University

TrichomeShell Activity – 41.6%

• Develops consumer products which are characterized by full repeatability per unit of product, while controlling the composition and dosage of the active ingredients.
• Patent (PCT) on the manufacturing methods and the materials used to manufacture its products.
• Develops unique manufacturing solutions for its products to enable large scale production and quality assurance
• Engages in the development of additional technologies and products to improve the accessibility of Cannabis products to end users

• Products are currently being sold in USA and Europe

Targene Activity – 52.3%

Producing active ingredients at scale

• Production of Cannabinoids (single molecule) and Cannabis cells (full spectrum) using breakthrough technology by using a liquid medium environment (bioreactor) for pharmagrade production of API's.

Advanced breeding methods(Gene editing)

• Using gene editing to improve plant traits such as: fungal resistance, change in cannabinoid compositions and increased yield.

PlantArc Bio Activity – 6.9% (TA:PLNT)

Genes discovery for the globalseedsindustry

• Innovative patented technology (DIP© Direct In Plant) for the discovery of genes that has positive effects on plants
• To date, the company found genes for yield improvement & drought resistance as well as herbicide tolerance and started to commercialize these genes to leading global seeds companies.

RNAi based spraysfor yield increase and insects' resistance

• Innovative RNAi-based applications for yield increase in canola, soybean and rice in collaboration with ICL, as well as the development of a tool for the destruction of the palm weevil in collaboration with Gadot-Agro

IPO

• During January 2021 PlantArc executed IPO in Tel Aviv Stock Exchange by raising approx. NIS 23.1 million*

^* Gross consideration from the allotment of shares and options under the IPO

Financial Highlights

2020 Revenues reached NIS 37 Million - an increase of 28% compared to 2019

Gross margin* in 2020 of 57% - compared to 48% in 2019

• The gross profit in 2020 was approx. NIS 21.1 Million and reflects an increase of approx. 52% compared to 2019.
• The gross margin in 2020 was 57% compared to 48% in 2019.

* Gross profit before the effect of changes in the fair value of biological assets

Adjusted profit* in 2020 reached NIS 18 Million - an increase of 95% compared to 2019

• Adjusted profit in 2020 was approx. NIS 18.1 Million and reflects an increase of 95% compared to 2019.
• Adjusted profit margin in 2020 is approx. 49%.

net profit (loss) excluding registration for one-time trading, share-based compensation and adjustments to the fair value of biological assets, net.

Building diverse revenue streams

Revenuesfrom Cannabis products in Israel

Revenuesfrom export of Cannabis products worldwide

Revenuesfrom royalties from subfarms and international collaborations

Expanding to additional sections within the Cannabis value chain

Value overflow from Seach's subsidiaries

Thank you! Seach Medical Group

www.seach.co.il

officemgr@seach.co.il